April Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
April Robinson has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Angela H. Pegram
Wingate University School of Pharmacy, 515 North Main Street, Wingate, NC 28174, United States
1 shared publication Dawn Battise
1 shared publication- Dawn M. Battise
Wingate University School of Pharmacy, 515 North Main Street, Wingate, NC 28174, United States
1 shared publication Delilah McCarty
Wingate University, Wingate, NC, USA
1 shared publicationJanine Douglas
Wingate University, Wingate, NC, USA
1 shared publication- Jennifer A. Wilson
Wingate University School of Pharmacy, 515 North Main Street, Wingate, NC 28174, United States
1 shared publication
Latest Publications
- 1 November 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (6) , 1151-1159
Traditional lecture versus jigsaw learning method for teaching Medication Therapy Management (MTM) core elements
- 1 November 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (6) , 1151-1159
Traditional lecture versus jigsaw learning method for teaching Medication Therapy Management (MTM) core elements
- Open Access
- 7 October 2016
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 11 (1) , 4-11
Novel oral anticoagulants for acute coronary syndrome
Acute coronary syndrome (ACS) is a cardiovascular condition with a multifactorial pathophysiology that includes atherosclerotic plaques, platelet activation and thrombin production, among others. Thrombin production and the prothrombotic state of ACS patients have provided a role for anticoagulants to treat patients during the acute event and has led to subsequent research for the post-acute state. Warfarin has an indication for ACS, however, it is restricted to specific patients and many factors limit its use. Therefore, novel oral anticoagulants (NOACs) are being explored for ACS. Limitations for the use of NOACs in ACS are centered on the increased risk of bleeding that occurs when these agents are added to the current standard of care with dual antiplatelet therapy. Rivaroxaban is the only NOAC that has achieved approval in Europe for this indication with none of the NOAC currently approved in the US for use in ACS. Ongoing studies for rivaroxaban and apixaban may provide evidence to further clarify the place in therapy for NOAC agents in ACS management.
- 7 October 2016
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 11 (1) , 4-11
Open AccessNovel oral anticoagulants for acute coronary syndrome
Acute coronary syndrome (ACS) is a cardiovascular condition with a multifactorial pathophysiology that includes atherosclerotic plaques, platelet activation and thrombin production, among others. Thrombin production and the prothrombotic state of ACS patients have provided a role for anticoagulants to treat patients during the acute event and has led to subsequent research for the post-acute state. Warfarin has an indication for ACS, however, it is restricted to specific patients and many factors limit its use. Therefore, novel oral anticoagulants (NOACs) are being explored for ACS. Limitations for the use of NOACs in ACS are centered on the increased risk of bleeding that occurs when these agents are added to the current standard of care with dual antiplatelet therapy. Rivaroxaban is the only NOAC that has achieved approval in Europe for this indication with none of the NOAC currently approved in the US for use in ACS. Ongoing studies for rivaroxaban and apixaban may provide evidence to further clarify the place in therapy for NOAC agents in ACS management.
- 1 November 2015
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 7 (6) , 876-883
Assessment of a new evaluation tool in a doctoral candidate seminar course
- 1 November 2015
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 7 (6) , 876-883
Assessment of a new evaluation tool in a doctoral candidate seminar course